Mankind Pharma withdraws some credit ratings, plans investor meetings

Mankind Pharma Limited informed stock exchanges on November 13, 2025, about the withdrawal of its credit rating for commercial paper amounting to ₹3,500 crore. This withdrawal was initiated at the company’s request by ICRA Limited, which had previously assigned an (ICRA) A1+ rating.

The company also provided an update on its outstanding credit ratings. These include a rating of (ICRA) AA+/Stable for Non-Convertible Debentures totaling ₹5,000 crore, an (ICRA) A1+ rating for commercial paper worth ₹1,500 crore, and a combined (ICRA)AA+ (Stable)/(ICRA)A1+ rating for long-term/short-term fund-based limits amounting to ₹1,250 crore. All these outstanding ratings are designated as "Outstanding."

Separately, Mankind Pharma announced its participation in the Avendus Spark INDX 2025 – The New Code for India's Growth investor conference in Mumbai on November 18, 2025. Company officials will engage in one-on-one and group meetings. The company explicitly stated that no unpublished price-sensitive information would be shared during this event.